PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21841039-4 2011 The absence of Abcc2 caused a decrease in total clearance of MTX relative to WT mice at all dose levels yet was accompanied by compensatory increases in renal excretion and metabolism to 7-hydroxymethotrexate (7OH-MTX). 7-hydroxymethotrexate 187-208 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 15-20 29618584-7 2018 Mrp2/3/4 alteration changed the distribution of MTX and 7OH MTX in plasma and tissues. 7-hydroxymethotrexate 56-63 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 0-4 21566011-7 2011 The absence of Abcc2 and/or Abcg2 also led to significantly increased liver and kidney levels of 7OH-MTX. 7-hydroxymethotrexate 97-104 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 15-20 21566011-2 2011 We have shown before that ABCC2, ABCC3, and ABCG2 together influence the pharmacokinetics of the anticancer and antirheumatic drug methotrexate (MTX) and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX) after intravenous MTX administration. 7-hydroxymethotrexate 175-196 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 26-31 21566011-2 2011 We have shown before that ABCC2, ABCC3, and ABCG2 together influence the pharmacokinetics of the anticancer and antirheumatic drug methotrexate (MTX) and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX) after intravenous MTX administration. 7-hydroxymethotrexate 198-205 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 26-31 19996279-0 2009 Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. 7-hydroxymethotrexate 135-156 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 0-5 19996279-0 2009 Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. 7-hydroxymethotrexate 135-156 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 7-11 19996279-7 2009 Furthermore, the urinary and fecal excretion of the nephrotoxic metabolite 7OH-MTX were increased 27- and 7-fold, respectively, in Abcc2;Abcc3;Abcg2-/- mice. 7-hydroxymethotrexate 75-82 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 131-136 19996279-8 2009 Thus, Abcc2, Abcc3, and Abcg2 together mediate the rapid elimination of MTX and 7OH-MTX after i.v. 7-hydroxymethotrexate 80-87 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 6-11 19383815-0 2009 Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. 7-hydroxymethotrexate 130-151 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 52-57 19383815-11 2009 CONCLUSIONS: Abcc2 and Abcg2 together are major determinants of MTX and 7OH-MTX pharmacokinetics. 7-hydroxymethotrexate 72-79 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 13-18 19383815-0 2009 Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. 7-hydroxymethotrexate 130-151 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 59-63 19383815-2 2009 We investigated the possibly overlapping roles of Abcg2 and Abcc2 in the elimination of the anticancer drug methotrexate (MTX) and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX). 7-hydroxymethotrexate 152-173 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 60-65 19088030-0 2008 Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. 7-hydroxymethotrexate 113-134 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 10-15 19088030-9 2008 The plasma AUCi.v.s of 7OH-MTX were 6.0-fold and 4.3-fold increased in Abcc2(-/-) and Abcc2;Abcc3(-/-) mice, respectively, leading to increased urinary excretion. 7-hydroxymethotrexate 23-30 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 71-76 19088030-9 2008 The plasma AUCi.v.s of 7OH-MTX were 6.0-fold and 4.3-fold increased in Abcc2(-/-) and Abcc2;Abcc3(-/-) mice, respectively, leading to increased urinary excretion. 7-hydroxymethotrexate 23-30 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 86-91 19088030-10 2008 The biliary excretion of 7OH-MTX was 5.8-fold reduced in Abcc2(-/-) but unchanged in Abcc2;Abcc3(-/-) mice. 7-hydroxymethotrexate 25-32 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 57-62 19088030-11 2008 7OH-MTX accumulated substantially in the liver of Abcc2(-/-) and especially Abcc2;Abcc3(-/-) mice. 7-hydroxymethotrexate 0-7 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 50-55 15313923-3 2004 We hypothesized that benzimidazoles interfere with the clearance of MTX and/or 7-hydroxymethotrexate by inhibition of the ATP-binding cassette drug transporters BCRP and/or MRP2, two transporters known to transport MTX and located in apical membranes of epithelia involved in drug disposition. 7-hydroxymethotrexate 79-100 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 173-177 19088030-11 2008 7OH-MTX accumulated substantially in the liver of Abcc2(-/-) and especially Abcc2;Abcc3(-/-) mice. 7-hydroxymethotrexate 0-7 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 76-81 19088030-12 2008 CONCLUSIONS: Abcc2 is important for (biliary) excretion of MTX and its toxic metabolite 7OH-MTX. 7-hydroxymethotrexate 88-95 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 13-18 19088030-13 2008 When Abcc2 is absent, Abcc3 transports MTX and 7OH-MTX back from the liver into the circulation, leading to increased plasma levels and urinary excretion. 7-hydroxymethotrexate 47-54 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 5-10